# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059375
Filing Date
2025-04-28
Accepted
2025-04-28 16:46:41
Documents
6
Period of Report
2024-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | lxeo-def_14a-2025_proxy.htm | DEF 14A | 916450
2 | GRAPHIC | img209845168_0.jpg | GRAPHIC | 249964
3 | GRAPHIC | img209845168_1.jpg | GRAPHIC | 9749
4 | GRAPHIC | img209845168_2.jpg | GRAPHIC | 3730
5 | GRAPHIC | img209845168_3.jpg | GRAPHIC | 416173
6 | GRAPHIC | img209845168_4.jpg | GRAPHIC | 188112
| Complete submission text file | 0000950170-25-059375.txt |  | 2112248

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41855 | Film No.: 25881207
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)